EULAR recommendations for the management of Behçet's syndrome: 2025 update - PubMed
5 hours ago
- #Behçet's syndrome
- #EULAR recommendations
- #rheumatology
- The 2025 update of EULAR recommendations for managing Behçet's syndrome involved a task force of 29 members from 11 countries, including various specialists and patient research partners.
- The update process included a Delphi survey, systematic literature review, and formulation of PICO questions to develop and modify recommendations.
- The updated recommendations consist of 5 overarching principles and 12 recommendations, with 1 new recommendation, 7 modified, and 4 with wording changes.
- Overarching principles emphasize recognizing the relapsing-remitting nature of the disease, individualized treatment, multidisciplinary approach, patient education, and shared decision-making.
- For mucocutaneous and joint involvement, colchicine is recommended as first-line treatment, with apremilast and TNFα inhibitors for refractory cases.
- For organ involvement, aggressive treatment with glucocorticoids and immunosuppressives is recommended, with early use of TNFα monoclonal antibodies for severe manifestations.
- The recommendations aim to improve the quality of care for Behçet's syndrome patients by incorporating new evidence and expert opinion.